Menjugate (N. Meningitidis Group C (Strain C11) Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm19)

Menjugate is a conjugate vaccine that targets the polysaccharide capsule of Neisseria meningitidis group C to prevent meningococcal disease.

• Meningococcal group C disease: provides active immunity to prevent invasive meningococcal disease caused by Neisseria meningitidis group C.
• Outbreak control: helps limit the spread of group C meningococcal infections during community outbreaks.
• Travel to endemic areas: reduces the risk of acquiring group C meningococcal disease for travelers to regions with known circulation.

• Menjugate induces active immunity by presenting the Neisseria meningitidis group C polysaccharide covalently linked to the diphtheria toxoid CRM197. The conjugate is taken up by antigen‑presenting cells, processed, and displayed to T‑cells, which then stimulate B‑cells to produce high‑affinity, class‑switched antibodies that neutralize the bacterial capsule and prevent invasive infection.

Common Side Effects

• Injection site pain: mild to moderate discomfort at the injection site.
• Redness or swelling: localized erythema or edema.
• Fever: transient low‑grade temperature rise.
• Headache: mild headache within 24 hours.
• Fatigue: temporary tiredness.
• Myalgia: muscle aches.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical attention.
• Hypotension: sudden drop in blood pressure post‑vaccination.
• Seizures: rare neurologic events.
• Guillain‑Barré syndrome: extremely rare autoimmune neuropathy.
• Severe local reaction: extensive necrosis or ulceration at injection site.

Before administering Menjugate, consider the following precautions:

• Screen for hypersensitivity: avoid in persons with known allergy to any vaccine component.
• Delay vaccination: postpone if the individual has an acute moderate or severe illness.
• Pregnancy: use only when the benefit outweighs potential risk, as safety data are limited.
• Concurrent vaccines: can be co‑administered according to national immunisation schedules.
• Immunocompromised patients: vaccine response may be reduced; assess need for booster doses.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Vaccines may interact with other agents that affect the immune system.

Major Interactions (Avoid)

• Live bacterial vaccines (e.g., oral typhoid) given within 4 weeks: may diminish immune response to either vaccine.

Moderate Interactions (Monitor Closely)

• Immunoglobulins or blood products: may interfere with antibody formation if administered within 3 days before or after vaccination.
• Immunosuppressive therapy: can reduce the immunogenicity of Menjugate.
• Antipyretics (e.g., acetaminophen): may mask fever but generally do not affect vaccine efficacy.
• Other vaccines administered simultaneously: monitor for additive local reactions.